Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
4931.05 | 8,442 Cr | 27.89 | 13.62 | 2.46 | 49.51 | 65.17 | 32.81 | ||
497.00 | 8,406 Cr | 23.92 | 2.67 | 0.00 | 10.07 | 8.99 | 6.29 | ||
654.95 | 8,403 Cr | 26.37 | 23.76 | 0.16 | 42.02 | 46.06 | 36.87 | ||
3380.10 | 8,112 Cr | 19.65 | 9.43 | 3.49 | 42.11 | 52.41 | 25.64 | ||
176.15 | 8,016 Cr | 22.13 | 2.98 | 0.45 | 13.08 | 16.13 | 10.51 | ||
420.00 | 7,919 Cr | 50.94 | 3.25 | 0.12 | 6.35 | 8.41 | 4.29 | ||
603.60 | 7,387 Cr | 47.19 | 9.00 | 0.00 | 20.63 | 23.80 | 17.20 | ||
| Median: 7 Co. | — | 603.60 | 8,112 Cr | 26.37 | 9.00 | 0.16 | 20.63 | 23.80 | 17.20 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Shilpa Medicare Ltd (SHILPAMED) is currently trading at 407.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Shilpa Medicare Limited is an Indian pharmaceutical company specializing in APIs, formulations, and biologics, with a global presence in over 50 countries. In 3Q FY26, Shilpa achieved its highest quarterly revenue of INR 411 crores, marking a 28% growth YoY, driven by significant advances in the formulation and biologics segments. The company has launched NorUDCA, a first-in-class therapy for Non-Alcoholic Fatty Liver Disease (NAFLD), through strategic partnerships, enhancing its domestic market position and preparing for international regulatory approvals. Shilpa's focus on differentiated, high-value products and integrated CDMO solutions is supported by a strategic partnership with Orion Corporation and advanced pipeline developments in biosimilars and recombinant human albumin. Substantial investments in R&D and manufacturing capacity expansions have led to marked improvements in the company's adjusted ROCE and underline its commitment to innovative healthcare offerings.
Over the past 52 weeks, Shilpa Medicare Ltd has traded between a low of ₹260.00 and a high of ₹501.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Shilpa Medicare Ltd has a market capitalization of approximately 7,919.11. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Shilpa Medicare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 50.94 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7,919.11 Cr, Shilpa Medicare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Shilpa Medicare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Shilpa Medicare Ltd is 50.94. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
As of early 2026, Shilpa Medicare's market capitalization is approximately ₹6,318.27 crore, placing it in the mid-cap category within the pharmaceutical sector.
Bearish
2
Neutral
6
Bullish
6
Bearish
10
Neutral
6
Bullish
30
Bearish
8
Neutral
0
Bullish
24
Shilpa Medicare Limited is an Indian pharmaceutical company specializing in APIs, formulations, and biologics, with a global presence in over 50 countries.
In 3Q FY26, Shilpa achieved its highest quarterly revenue of INR 411 crores, marking a 28% growth YoY, driven by significant advances in the formulation and biologics segments.
The company has launched NorUDCA, a first-in-class therapy for Non-Alcoholic Fatty Liver Disease (NAFLD), through strategic partnerships, enhancing its domestic market position and preparing for international regulatory approvals.
Shilpa's focus on differentiated, high-value products and integrated CDMO solutions is supported by a strategic partnership with Orion Corporation and advanced pipeline developments in biosimilars and recombinant human albumin.
Substantial investments in R&D and manufacturing capacity expansions have led to marked improvements in the company's adjusted ROCE and underline its commitment to innovative healthcare offerings.
Pharmaceuticals & Biotechnology
Pharmaceuticals
7,919 Cr
Moderate Risk
50.9
32.2
0.7
3.3
501.60
260.00
Sales CAGR
Profit CAGR
ROE
ROCE
